Abstract
Adverse reactions caused by drugs can be divided into two main groups, type A and type B reactions. Type A reactions represent nearly 80 %–85 % of these side effects and are caused by predictable pharmacological actions of the drug, while type B reactions develop on the basis of individual predisposition (idiosyncratic reactions, immune-mediated and nonimmune-mediated hypersensitivity reactions) and account for 15 %–20 % of adverse effects. The skin is the organ most commonly, but not exclusively, affected in drug hypersensitivity reactions both in the immune-mediated (allergic) and in the nonimmune-mediated (pseudoallergic) forms; these reactions are observed in 2 %–3 % of hospitalised patients. Immune-mediated drug hypersensitivity reactions comprise a heterogeneous group of diseases which can be classified according to Gell and Coombs (antibody-mediated drug hypersensitivity reactions: type I, IgE; type II and III, IgG; and type IV, T cell mediated). After better understanding of T-cell functions and discovery of subgroups, the late type IV reaction has been further subdivided in the revised form of Gell and Coombs classification (type IVa, T helper 1; type IVb, T helper 2; type IVc, T cytotoxic mediated and type IVd). Nonimmune-mediated hypersensitivity reactions are the so-called pseudoallergic reactions, which usually imitate IgE-mediated reactions with wheal and oedema formation, but sometimes anaphylaxis can also develop. These pseudoallergic reactions tend to arise less rapidly than true IgE-mediated allergies, they require higher doses of the drugs and neither IgE nor T-cell reactions can be demonstrated later. Non-specific histamine release, arachidonic acid pathway activation, bradykinin pathway alteration and complement activation can be detected in the background. Nonsteroidal anti-inflammatory drugs (NSAIDs), plasma expanders and radiocontrast media are the most common causes of pseudoallergic reactions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AGEP:
-
Acute generalised exanthematous pustulosis
- DiHS:
-
Drug-induced hypersensitivity syndrome
- DRESS:
-
Drug reaction with eosinophilia and systemic symptoms
- HSS:
-
Hypersensitivity syndrome
- LTT:
-
Lymphoblast transformation test
- MDE:
-
Maculopapular drug eruption
- NSAIDs:
-
Nonsteroidal anti-inflammatory drugs
- SJS:
-
Stevens-Johnson syndrome
- SSSS:
-
Staphylococcus scalded skin syndrome
- TEN:
-
Toxic epidermal necrolysis
Reference
Kardaun SH, Sidoroff A, Valeyrie-Allanore, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609–11.
Further Reading
Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33–6.
Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115:149–53.
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.
Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87:144–8.
Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7(2):142–60.
Pichler WJ, editor. Drug hypersensitivity. Basel: Karger; 2007.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68(9):1781–90.
Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209(2):123–9.
Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mochenhaupt M. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol. 2008;58(1):33–40.
Sidoroff A, Halevy S, Bouwes Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J Cutan Pathol. 2001;28:113–9.
Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India. 2013;69(4):375–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Szegedi, A., Remenyik, E. (2015). Drug Hypersensitivity Reactions. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D’Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45139-7_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-45139-7_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45138-0
Online ISBN: 978-3-662-45139-7
eBook Packages: MedicineMedicine (R0)